

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2007

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2007 (Rs. in thousands)						
Sr. No.	Particulars	Quarter ended 30.09.2007 (Audited)	Quarter ended 30.09.2006 (Audited)	Half year ended 30.09.2007 (Audited)	Half year ended 30.09.2006 (Audited)	Year ended 31.03.2007 (Audited)
1.	Net Sales	2,355,885	2,191,068	4,629,917	4,033,077	8,509,754
2.	Other Income	57,032	10,451	98,901	19,700	121,105
3.	Total Expenditure (a+b+c+d+e+f)	1,754,779	1,651,366	3,439,550	3,080,641	6,266,690
	a. (Increase)/decrease in stock in trade	(38,333)	(263,320)	(214,012)	(309,939)	(218,877)
	b. Consumption of Raw Materials	1,021,328	1,231,042	2,108,883	2,247,629	4,211,178
	c. Purchase of traded goods	75,914	105,135	137,141	143,429	165,824
	d. Power cost	202,100	178,396	406,387	280,245	620,715
	e. Employee cost	189,442	153,088	384,170	270,228	618,055
	f. Other Expenditure	304,328	247,025	616,981	449,049	869,795
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	658,138	550,153	1,289,268	972,136	2,364,169
5.	Interest and finance charges	9,201	18,448	18,126	35,018	77,618
6.	Depreciation	174,604	156,524	341,567	246,685	576,060
7.	Profit Before Taxation (4-5-6)	474,333	375,181	929,575	690,433	1,710,491
8.	Provision for current tax (Including Fringe Benefit Tax)	29,747	(3,911)	44,847	38,201	9,158
9.	Provision for deferred tax	4,527	19,357	(3,945)	16,772	117,831
10.	Net Profit (7-8-9)	440,059	359,735	888,673	635,460	1,583,502
11.	Paid-up equity share capital	500,000	500,000	500,000	500,000	500,000
12.	Reserves excluding revaluation reserves	9,845,963	8,182,354	9,845,963	8,182,354	8,905,315
13.	Earnings per share (Par value of Rs. 5/-)					
	- Basic	4.55	3.73	9.20	6.59	16.38
	- Diluted	4.40	3.71	8.89	6.56	16.30
14.	Aggregate of Non-Promoter Shareholding					
	- Number of Shares	39,098,427	39,098,427	39,098,427	39,098,427	39,098,427
	- Percentage of shareholding	39.09%	39.09%	39.09%	39.09%	39.09%

SEGMENT REPORTING FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2007 (Rs. in thousands)						
Sr. No.	Particulars	Quarter ended 30.09.2007 (Audited)	Quarter ended 30.09.2006 (Audited)	Half year ended 30.09.2007 (Audited)	Half year ended 30.09.2006 (Audited)	Year ended 31.03.2007 (Audited)
1.	Segment revenue					
	a. Enzymes	224,526	313,520	477,247	580,407	1,151,789
	b. Pharma	2,138,970	1,898,632	4,172,901	3,492,263	7,422,843
	c. Unallocated	132,288	-	328,541	-	350,229
	Total	2,495,784	2,212,152	4,978,689	4,072,670	8,924,861
	Less: Inter-segment revenue	98,439	16,049	271,480	39,594	356,243
	Net sales/Income from operations	2,397,345	2,196,103	4,707,209	4,033,076	8,568,618
2.	Segment results					
	Profit before interest, depreciation and tax from each segment					
	a. Enzymes	52,351	122,547	118,513	241,320	439,878
	b. Pharma	739,103	724,135	1,525,632	1,315,332	2,321,587
	c. Unallocated	24,195	-	83,400	-	112,656
	Total	815,649	846,682	1,727,545	1,556,652	2,874,121
	Less: Interest	9,201	18,448	18,126	35,018	77,618
	Depreciation	174,604	156,524	341,567	246,685	576,060
	Unallocated corporate expenses	173,083	301,932	459,886	604,203	572,185
	Unallocable income	(15,572)	(5,402)	(21,609)	(19,687)	(62,242)
	Profit before tax	474,333	375,180	929,575	690,433	1,710,500
3.	Capital employed					
	a. Enzymes	430,297	471,557	430,297	471,457	656,874
	b. Pharma	7,256,630	6,214,157	7,256,630	6,214,157	6,853,699
	c. Unallocable corporate assets	4,653,848	4,337,228	4,653,848	4,337,228	4,056,480
	Less: Corporate liabilities	1,984,526	2,328,595	1,984,526	2,328,595	2,150,648
	Total capital employed	10,356,249	8,694,247	10,356,249	8,694,247	9,416,405
	Less: Revaluation Reserve	10,287	11,891	10,287	11,891	11,090
	Capital employed net of revaluation reserves	10,345,962	8,682,356	10,345,962	8,682,356	9,405,315

Note: The primary reporting of the Company has been performed on the basis of business segment. The Company is organised into two business segments, enzymes and active pharmaceutical ingredients ('Pharma'). Segments have been identified and reported based on the nature of the products, the risks and returns, the organisation structure and the internal financial reporting systems. The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter and half-year ended September 30, 2007.

CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2007 (Rs. in thousands)						
Sr. No.	Particulars	Quarter ended 30.09.2007 (Audited)	Quarter ended 30.09.2006 (Audited)	Half year ended 30.09.2007 (Audited)	Half year ended 30.09.2006 (Audited)	Year ended 31.03.2007 (Audited)
1.	Net Sales	2,789,928	2,489,960	5,498,235	4,610,095	9,857,311
2.	Other Income	19,192	8,611	29,084	17,150	38,183
	Total Income	2,809,120	2,498,571	5,527,319	4,627,245	9,895,494
3.	Total Expenditure (a+b+c+d+e+f)	1,985,364	1,830,722	3,926,589	3,407,204	7,022,480
	a. (Increase)/decrease in stock in trade	(32,937)	(263,320)	(231,555)	(309,939)	(218,939)
	b. Consumption of Raw Materials & Traded goods	1,112,089	1,308,541	2,335,961	2,394,123	4,560,875
	c. Purchase of Traded goods	75,914	105,135	137,141	143,430	165,824
	d. Power cost	202,995	185,216	408,076	293,709	619,567
	e. Employee cost	296,320	224,244	593,805	404,500	909,099
	f. Other Expenditure	330,983	270,906	683,161	481,381	986,054
4.	Profit before Interest, Depreciation & Taxes (1+2-3)	823,756	667,849	1,600,730	1,220,041	2,873,014
5.	Interest and finance charges	26,718	21,641	54,257	38,351	97,563
6.	Depreciation	233,558	177,522	453,955	287,161	665,483
7.	Profit Before Taxation from ordinary activities (4-5-6)	563,480	468,686	1,092,518	894,529	2,109,968
8.	Provision for current tax (including Fringe Benefit Tax)	21,667	3,475	46,780	49,561	18,133
9.	Provision for deferred tax	15,782	18,869	5,458	14,915	150,986
10.	Net Profit before minority interest (7-8-9)	526,031	446,342	1,040,280	830,053	1,940,849
11.	Add/(Less): Minority interest	13,556	7,056	27,675	12,450	61,767
12.	Net Profit (10+11)	539,587	453,398	1,067,955	842,503	2,002,616
13.	Paid-up equity share capital	500,000	500,000	500,000	500,000	500,000
14.	Reserves excluding revaluation reserves	11,294,909	9,239,948	11,294,909	9,239,948	10,174,980
15.	Earnings per share (Par value of Rs 5/-)					
	- Basic	5.58	4.70	11.05	8.74	20.72
	- Diluted	5.40	4.67	10.68	8.56	20.62

Notes: 1. The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in India and comply with the Accounting Standard (AS 21) on Consolidated Financial Statements, issued by the Institute of Chartered Accountants of India to reflect the financial position and the results of operations of Biocon together with its wholly owned subsidiaries Syngene and Clinigene and its 51% JV company, Biocon Biopharmaceuticals. 2. The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter and half-year ended September 30, 2007.

Notes: 1. The above audited results were reviewed by the Audit Committee on October 17, 2007 and then taken on record by the Board of Directors of the Company at its meeting held on October 18, 2007. There are no qualifications in Auditors' Reports for the period. 2. On October 1, 2007, the Company consummated the sale of its Enzymes Business in accordance with the business sale agreement entered into with M/s Novozymes South Asia Private Limited ("buyer"), pursuant to the approval of the shareholders of the Company on September 3, 2007, for an overall sale consideration of Rs 467 crores. As part of the sale agreement, the Company has also entered into a lease agreement and support services agreement to lease certain fixed assets and to provide certain specified support services to the buyer, effective October 1, 2007. 3. The profit before taxes includes Rs.12,924; Rs. 86,999; Rs. 38,795; Rs. 182,338; Rs. 357,030 from operating activities of discontinuing operations, for each of the aforesaid periods respectively. 4. The profit after taxes includes Rs.9,808; Rs.69,306; Rs.28,262; Rs.139,579; Rs. 260,339 from operating activities of discontinuing operations for each of the aforesaid periods respectively. 5. Total number of shareholder complaints pending at the beginning of the quarter was Nil. Complaints received during the quarter were 106. All complaints received during the quarter were resolved and there were no complaints pending for redressal as at September 30, 2007. 6. The figures have been reclassified wherever required, to conform with the classification in the financial statements for the quarter ended September 30, 2007.

For and on behalf of the Board

Sd/-
Kiran Mazumdar-Shaw
 Managing Director

Place: Bangalore
 Date: October 18, 2007